Breaking News

WuXi Biologics Introduces TrueSite TI Cell Line Platform

Leverages targeted integration technique to streamline clone screening and guarantee expression stability.

Author Image

By: Charlie Sternberg

Associate Editor

WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has launched TrueSite TI, a targeted integration (TI)-based CHO cell line platform designed to reshape biologics development by accelerating timelines, enhancing product quality, and ensuring consistent scalability for antibody and complex protein therapies. Targeted integration is a cellular engineering technique that delivers target expression units to predefined, validated locations in host cel...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters